Historique
Périodique
A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence
(Une étude pilote sur le piracetam et le "ginkgo biloba" pour le traitement de la dépendance à la cocaïne)
Auteur(s) :
KAMPMAN, K. ;
MAJEWSKA, M. D. ;
TOURIAN K. ;
DACKIS, C. ;
CORNISH, J. ;
POOLE, S. ;
O'BRIEN, C.
Année
2003
Page(s) :
437-448
Langue(s) :
Français
Refs biblio. :
48
Domaine :
Drogues illicites / Illicit drugs
Note générale :
Addictive Behaviors, 2003, 28, (3), 437-448
Note de contenu :
tabl. ; graph.
Résumé :
ENGLISH :
Background : Chronic cocaine use is associated with cognitive deficits that may reduce the effectiveness of psychosocial treatment and promote relapse in newly abstinent cocaine-dependent patients. Nootropic agents, such as piracetam and ginkgo biloba, may improve cognitive function and reduce the incidence of relapse in these patients. Methods : This was a 10-week, double-blind, placebo-controlled pilot trial involving 44 cocaine-dependent subjects. Subjects received either piracetam (4.8 g/day), ginkgo biloba (120 mg/day), or placebo. Subjects were required to attain abstinence from cocaine during a 2-week baseline phase demonstrated by providing at least one benzoylecgonine (BE)-negative urine toxicology screen. Outcome measures included treatment retention, urine toxicology screens, Clinical Global Impression (CGI) scores, and results from the Addiction Severity Index (ASI). Results : Ginkgo biloba was not superior to placebo in any outcome measure. Piracetam was associated with more cocaine use and lower CGI scores compared to placebo. Conclusions : Neither piracetam nor ginkgo biloba appears to be a promising medication for the treatment of cocaine dependence. (Editor's abstract.)
Affiliation :
Univ. PA Treatment Res. Ctr, 3900 Chestnut st, Philadelphia, PA 19104. E-mail : kampman_kmail.trc.upenn.edu
Etats-Unis. United States.
Etats-Unis. United States.
Cote :
A01889